GU Cancers 2025 | Treating patients with prostate cancer who progress on 177Lu-PSMA-617
Umang Swami
• 13 Feb 2025
Findings from the TheraP trial (NCT03392428) have demonstrated the efficacy of cabazitaxel for patients with prostate cancer who have not been treated with it before and have progressed on 177Lu-PSMA-617. Umang Swami, MD, MS, University of Utah, Salt Lake City, UT, comments on additional treatment options for patients who progress on radionuclides 177Lu-PSMA-617, such as T-cell engagers and other radiopharmaceuticals. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
